

=//

Product Information Sheet

Monoclonal Anti-c-Myc

Catalogue No. MA1028

Lot No. 08A12

Clone: IMD-3

Ig type: mouse IgG2a

Size: 100µg/vial

Specificity


Human.

No cross reactivity with other proteins.

Recommended application

Western blot

Immunohistochemistry(P)
Immunocytochemistry



Immunogen

Synthetic peptide corresponding to residues 408-439 of the human p62^{c-Myc} protein.

Purification

Purified by the goat anti-mouse IgG affinity chromatography.

Application

Western blot

At 4µg/ml with the appropriate system to detect c-Myc in cells and tissues.

Immunohistochemistry(P)

At 8µg/ml to detect c-Myc in formalin fixed and paraffin embedded tissues.

Immunocytochemistry Suitable

Other applications have not been tested.

Optimal dilutions should be determined by end user.

Formulation

Lyophilized from 1.2% sodium acetate, with 2mg BSA and 0.01mg NaN_3 as preservative.

Reconstitution

1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, the antibody concentration will be 100µg/ml.

To reorder contact us at:

Antagene, Inc.

Toll Free: 1(866)964-2589 email: Info@antageneinc.com

Storage

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for longer time.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE.

BACKGROUND

C-Myc is an oncogene that functions both in the stimulation of cell proliferation and in apoptosis. c-Myc elicits its oncogenic activity by causing immortalization, and to a lesser extent the transformation of cells, in addition to several other mechanisms. The c-MYC proto-oncogene encodes a transcription factor that is critical for cell growth and proliferation. It is one of the genes frequently altered in cancer cells in which it exhibits constitutive activity. Downregulation of c-Myc is critical for 2-Methoxyestradiol (2ME2)-induced oxidative stress and apoptosis in AML cells. And its up-regulation is important for promoting lymphocyte cell division, and demonstrating that GFP-c-Myc expression is a marker of proliferating lymphocytes in vivo.

REFERENCE

- 1. Liao D, Thakur A, Wu J, Biliran H, Sarkar FH. Perspectives on c-Myc, Cyclin D1, and Their Interaction in Cancer Formation, Progression, and Response to Chemotherapy.Crit Rev Oncog. 2007;13(2):93-158.
- 2. Britton S, Salles B, Calsou P. c-MYC protein is degraded in response to UV irradiation.Cell Cycle. 2007 Oct 2;7(1)
- 3. Chow JM, Liu CR, Lin CP, Lee CN, Cheng YC, Lin S, Liu HE. Downregulation of c-Myc determines sensitivity to 2-methoxyestradiol-induced apoptosis in human acute myeloid leukemia. Exp Hematol. 2008 Feb;36(2):140-8.
- 4. Huang CY, Bredemeyer AL, Walker LM, Bassing CH, Sleckman BP. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse.Eur J Immunol. 2008 Jan 14.